KIT and gastrointestinal stromal tumor: Applying advanced next-generation sequencing technologies for detection of KIT mutations in plasma-derived ctDNA further confirmed the substantial intrapatient heterogeneity of KIT mutations in patients with later-line GIST (25, 26).